Clinical Trials Browser

Completed × INDUSTRY × neratinib × Clear all

NCT04388384 2025-08-06

ELEANOR

Breast Neoplasms

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast Neoplasms

NCT02400476 2022-05-06

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Phase 2 Completed

563 enrolled 16 charts

Breast Neoplasms

NCT00878709 2021-06-11

ExteNET

Phase 3 Completed

2,840 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT01808573 2021-06-11

NALA

Phase 3 Completed

621 enrolled 21 charts 2 FDA

HER2+ Metastatic Breast Cancer (MBC)

NCT01128842 2018-12-19

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Phase 1 Completed

7 enrolled 13 charts

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT00768469 2018-11-19

Study Evaluating Safety And Tolerability, Solid Tumor

Phase 1 Completed

10 enrolled 11 charts

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Phase 1 Completed

63 enrolled 26 charts

Neoplasms

NCT00146172 2018-09-17

Study Evaluating HKI-272 in Tumors

Phase 1 Completed

73 enrolled 20 charts

Breast Neoplasms, Neoplasms

NCT00397046 2018-09-14

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Phase 1 Completed

21 enrolled 13 charts

Neoplasms

NCT00741260 2018-09-05

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Phase 1/2 Completed

105 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00915018 2018-08-22

NEFERTT

Phase 2 Completed

479 enrolled 13 charts

Breast Neoplasms

NCT00300781 2018-08-14

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Phase 2 Completed

136 enrolled 11 charts

Breast Neoplasms, Neoplasms

NCT00706030 2018-08-09

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Phase 1/2 Completed

92 enrolled 14 charts

Breast Neoplasms

NCT00777101 2018-08-09

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2 Completed

233 enrolled 16 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00445458 2018-07-26

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Phase 1/2 Completed

110 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT00398567 2018-07-24

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Phase 1/2 Completed

45 enrolled 15 charts

Breast Neoplasms

NCT01827267 2018-07-03

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Phase 2 Completed

62 enrolled 12 charts

Lung Neoplasms

NCT00958724 2018-06-28

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Phase 1 Completed

6 enrolled 13 charts

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT00266877 2018-04-13

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

172 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00366600 2017-09-11

Study Evaluating HKI-272 Administered to Healthy Subjects

Phase 1 Completed

Breast Neoplasms

NCT00708903 2012-05-14

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Phase 1 Completed

Breast Neoplasms